Emergency Approvals for COVID-19: Evolving Impact on Obligations to Patients in Clinical Care and Research.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 33136427.
- Also identified by DOI 10.7326/M20-6703 and PMC identifier 7643168.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
There currently is debate regarding whether U.S. institutions and clinicians may or should restrict patient access to COVID-19 drugs and vaccines that have been granted emergency use authorization by the U.S. Food and Drug Administration. The authors provide their views on the legal, ethical, and clinical ramifications of such restriction.
Medical subject headings
- COVID-19
- Emergencies
- Pneumonia, Viral